Cardiovascular Intervention and Therapeutics

, Volume 34, Issue 1, pp 34–39 | Cite as

Satisfactory arterial repair 1 year after ultrathin strut biodegradable polymer sirolimus-eluting stent implantation: an angioscopic observation

  • Takayuki IshiharaEmail author
  • Masaki Awata
  • Osamu Iida
  • Masashi Fujita
  • Masaharu Masuda
  • Shin Okamoto
  • Kiyonori Nanto
  • Takashi Kanda
  • Takuya Tsujimura
  • Masaaki Uematsu
  • Toshiaki Mano
Original Article


The ultrathin strut biodegradable polymer sirolimus-eluting stent (Orsiro, O-SES) exhibits satisfactory clinical outcomes. However, no report to date has documented the intravascular status of artery repair after O-SES implantation. We examined 5 O-SES placed in 4 patients (age 65 ± 12 years, male 75%) presenting with stable angina pectoris due to de novo lesions in native coronary arteries. Coronary angioscopy was performed immediately after percutaneous coronary intervention and 1 year later. Angioscopic images were analyzed to determine the following: (1) dominant grade of neointimal coverage (NIC) over the stent; (2) maximum yellow plaque grade; and (3) existence of thrombus. Yellow plaque grade was evaluated both immediately after stent implantation and at the time of follow-up observation. The other parameters were evaluated at the time of follow-up examination. NIC was graded as: grade 0, stent struts exposed; grade 1, struts bulging into the lumen, although covered; grade 2, struts embedded in the neointima, but translucent; grade 3, struts fully embedded and invisible. Yellow plaque severity was graded as: grade 0, white; grade 1, light yellow; grade 2, yellow; and grade 3, intensive yellow. Angioscopic findings at 1 year demonstrated the following: dominant NIC grade 1, grade 2, and grade 3 in 1, 2, and 2 stents, respectively; all stents were covered to some extent; focal thrombus adhesion was observed in only 1 stent. Yellow plaque grade did not change from immediately after stent implantation to follow-up. O-SES demonstrated satisfactory arterial repair 1 year after implantation.


Angioscopy Arterial repair Ultrathin strut biodegradable polymer sirolimus-eluting stent 




Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

12928_2018_510_MOESM1_ESM.mpg (4.6 mb)
Angioscopic image of ultrathin strut biodegradable polymer sirolimus-eluting Stent (O-SES) 385 days after implantation (case number 1). Coronary angioscopic observation 1 year after O-SES (2.5 mm diameter by 18 mm length) implantation in the distal part of right coronary artery demonstrated that while stent struts were embedded in the neointima, but were translucently visible in the proximal segment, stent struts were fully embedded and invisible from middle to distal stented segment (MPG 4736 kb)


  1. 1.
    Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuilliomenet A, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet. 2014;384:2111–22.CrossRefGoogle Scholar
  2. 2.
    Windecker S, Haude M, Neumann FJ, Stangl K, Witzenbichler B, Slagboom T, et al. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial. Circ Cardiovasc Interv. 2015;8:e001441.CrossRefGoogle Scholar
  3. 3.
    von Birgelen C, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet. 2016;388:2607–17.CrossRefGoogle Scholar
  4. 4.
    Sakai S, Mizuno K, Yokoyama S, Tanabe J, Shinada T, Seimiya K, et al. Morphologic changes in infarct-related plaque after coronary stent placement: a serial angioscopy study. J Am Coll Cardiol. 2003;42:1558–65.CrossRefGoogle Scholar
  5. 5.
    Takano M, Mizuno K, Yokoyama S, Seimiya K, Ishibashi F, Okamatsu K, et al. Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy. J Am Coll Cardiol. 2003;42:680–6.CrossRefGoogle Scholar
  6. 6.
    Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47:2108–11.CrossRefGoogle Scholar
  7. 7.
    Awata M, Nanto S, Uematsu M, Morozumi T, Watanabe T, Onishi T, et al. Heterogeneous arterial healing in patients following paclitaxel-eluting stent implantation: comparison with sirolimus-eluting stents. J Am Coll Cardiol Interv. 2009;2:453–8.CrossRefGoogle Scholar
  8. 8.
    den Heijer P, Foley DP, Hillege HL, Lablanche JM, van Dijk RB, Franzen D, et al. The ‘Ermenonville’ classification of observations at coronary angioscopy—evaluation of intra- and inter-observer agreement. European Working Group on Coronary Angioscopy. Eur Heart J. 1994;15:815–22.CrossRefGoogle Scholar
  9. 9.
    Kurihara O, Okamatsu K, Mizuno K, Takano M, Yamamoto M, Kobayashi N, et al. Coronary atherosclerosis and risk of acute coronary syndromes in chronic kidney disease using angioscopy and the kidney disease: improving global outcomes (KDIGO) classification. Atherosclerosis. 2015;243:567–72.CrossRefGoogle Scholar
  10. 10.
    Ueda Y, Asakura M, Yamaguchi O, Hirayama A, Hori M, Kodama K. The healing process of infarct-related plaques. Insights from 18 months of serial angioscopic follow-up. J Am Coll Cardiol. 2001;38:1916–22.CrossRefGoogle Scholar
  11. 11.
    Higo T, Ueda Y, Oyabu J, Okada K, Nishio M, Hirata A, et al. Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study. J Am Coll Cardiol Imaging. 2009;2:616–24.CrossRefGoogle Scholar
  12. 12.
    Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T, et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation. 2007;116:910–6.CrossRefGoogle Scholar
  13. 13.
    Awata M, Uematsu M, Sera F, Ishihara T, Watanabe T, Fujita M, et al. Angioscopic assessment of arterial repair following biodegradable polymer-coated biolimus A9-eluting stent implantation. Comparison with durable polymer-coated sirolimus-eluting stent. Circ J. 2011;75:1113–9.CrossRefGoogle Scholar
  14. 14.
    Dai K, Matsuoka H, Kawakami H, Sato T, Watanabe K, Nakama Y, et al. Comparison of chronic angioscopic findings of bare metal stents, 1st-generation drug-eluting stents and 2nd-generation drug-eluting stents—Multicenter Study of Intra-coronary Angioscopy After Stent (MICASA). Circ J. 2016;80:1916–21.CrossRefGoogle Scholar
  15. 15.
    Akazawa Y, Matsuo K, Ueda Y, Nishio M, Hirata A, Asai M, et al. Atherosclerotic change at one year after implantation of Endeavor zotarolimus-eluting stent vs. everolimus-eluting stent. Circ J. 2014;78:1428–36.CrossRefGoogle Scholar
  16. 16.
    Karjalainen PP, Varho V, Nammas W, Mikkelsson J, Pietilä M, Ylitalo A, et al. Early neointimal coverage and vasodilator response following biodegradable polymer sirolimus-eluting vs. durable polymer zotarolimus-eluting stents in patients with acute coronary syndrome—HATTRICK-OCT trial. Circ J. 2015;79:360–7.CrossRefGoogle Scholar
  17. 17.
    Schwartz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol. 1998;81:14E–7E. Accessed 31 Oct 2016.
  18. 18.
    Foin N, Lee RD, Torii R, Guitierrez-Chico JL, Mattesini A, Nijjer S, et al. Impact of stent strut design in metallic stents and biodegradable scaffolds. Int J Cardiol. 2014;177:800–8.CrossRefGoogle Scholar
  19. 19.
    Guagliumi G, Sirbu V, Musumeci G, Gerber R, Biondi-Zoccai G, Ikejima H, et al. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. J Am Coll Cardiol Interv. 2012;5:12–20.CrossRefGoogle Scholar
  20. 20.
    Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435–41.CrossRefGoogle Scholar

Copyright information

© Japanese Association of Cardiovascular Intervention and Therapeutics 2018

Authors and Affiliations

  • Takayuki Ishihara
    • 1
    Email author return OK on get
  • Masaki Awata
    • 2
  • Osamu Iida
    • 1
  • Masashi Fujita
    • 3
  • Masaharu Masuda
    • 1
  • Shin Okamoto
    • 1
  • Kiyonori Nanto
    • 1
  • Takashi Kanda
    • 1
  • Takuya Tsujimura
    • 1
  • Masaaki Uematsu
    • 4
  • Toshiaki Mano
    • 1
  1. 1.Kansai Rosai Hospital Cardiovascular CenterAmagasakiJapan
  2. 2.Department of Cardiovascular MedicineOsaka National HospitalOsakaJapan
  3. 3.Onco-Cardiology Unit, Department of Cardiovascular MedicineOsaka International Cancer InstituteOsakaJapan
  4. 4.Institute for Clinical ResearchOsaka National HospitalOsakaJapan

Personalised recommendations